Sugi Predict

Sugi Predict / Compounds / SCHEMBL3239807

SCHEMBL3239807

SCHEMBL3239807

Cc1cc(F)ccc1C(=O)N1N(C2C3CC4CC(C3)CC2C4)C(=O)C1(C)C

nearest known ligand 0.33

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ POLB P06746 1/20 0.32
▸ PDE2A O00408 1/20 0.32
▸ EPHX2 P34913 1/20 0.32
▸ HCRTR1 O43613 1/20 0.32
▸ HCRTR2 O43614 1/20 0.32
▸ CNR2 P34972 1/20 0.32
▸ P2RX7 Q99572 2/20 0.32
▸ HSD11B1 P28845 2/20 0.31
▸ SIGMAR1 Q99720 1/20 0.31
▸ GRIN2B Q13224 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ SLC6A9 P48067 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2170049 0.91 HCRTR1 (0.40) MEN1KMT2APOLBPDE2AEPHX2
SCHEMBL2169955 0.90 CPS1 (0.36) KMT2AEPHX2
SCHEMBL2170679 0.89 HCRTR1 (0.38) EPHX2HCRTR1HCRTR2P2RX7HSD17B10
SCHEMBL2169753 0.88 P2RX7 (0.42) MEN1KMT2APOLBP2RX7HSD11B1
SCHEMBL2170598 0.88 CES2 (0.36) MEN1KMT2AEPHX2CNR2ALDH1A1
SCHEMBL2170340 0.86 HCRTR1 (0.42) KMT2AHCRTR1HCRTR2P2RX7
SCHEMBL2169787 0.86 HCRTR1 (0.38) MEN1KMT2AHCRTR1HCRTR2CNR2
SCHEMBL2170275 0.85 ALDH1A1 (0.40) MEN1KMT2APOLBEPHX2HSD11B1
SCHEMBL2169693 0.84 ITGB1 (0.42) MEN1KMT2APOLBP2RX7ALDH1A1
SCHEMBL2169055 0.82 HSD17B10 (0.39) MEN1KMT2APOLBEPHX2HCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 — — US disclosed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 — — US disclosed
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 — — US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 — — US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 — — US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 — — US disclosed
WO-2010050191-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVE AND PHARMACEUTICAL AGENT COMPRISING SAME 興和株式会社 (JP) 2010-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME HSD11B1, HSD11B2, HSD3B1 MEN1 490/4885KMT2A 3619/4885POLB 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.